XClose

UCL Queen Square Institute of Neurology

Menu

QS MS Centre: Vision Statement

The Queen Square Multiple Sclerosis (MS) Centre is a world-leading centre of MS research and clinical practice, working collaboratively to uncover basic disease mechanisms and translate this knowledge into new therapeutic strategies for the benefit of people with MS.

Strategic Approach 

  1. The Centre’s members have the full range of expertise needed to deliver on our translational vision. Our members include international leaders in the fields of experimental neuroinflammation, imaging measures of MS pathology and pathogenic mechanisms, proof-of-concept clinical trials, trial design, centralised image analysis, and symptomatic treatment including neurorehabilitation.

  2. The Centre promotes fundamental advances in our basic research laboratories, examines the new knowledge in our research clinics, and tests promising new treatments, for the benefit of people with MS. The Centre provides a collaborative environment for outstanding researchers and clinicians at UCL and the National Hospital to work with people affected by MS to achieve our vision.

  3. The Centre provides a collaborative environment for outstanding researchers and clinicians at UCL and the National Hospital to work with people affected by MS to achieve our vision.

  4. The Centre actively collaborates with other MS research and clinical centres, in the UK and internationally, to accelerate and enhance the quality of MS research and promote changes in clinical practice.

  5. Education and mentorship of young basic and clinical scientists from different disciplines is vital to our core mission.

Aims

  1. To use accurate experimental models of MS to understand the causes of irreversible disability, and in particular seek to understand why new lesions form and grow, how  progressive neurodegeneration develops, and how these processes cause symptoms, in order to help the community devise novel strategies for treating MS in all forms.
  2. Elucidate pathogenic mechanisms and identify novel treatment strategies through expert study of post mortem pathology, and immunological and other biomarkers from body fluids.
  3. Develop new imaging techniques for accurate and timely MS diagnosis, to understand MS pathophysiology and expedite the development of effective new disease modifying treatments.
  4. Perform central MRI analysis in multicentre trials of potential new treatments for MS. Develop new clinical trial design and analysis strategies with associated statistical methodology.
  5. Develop new clinical trial design and analysis strategies with associated statistical methodology.
  6. Test promising new therapies to modify the course of MS, with a focus on neuroprotection and repair in order to prevent and reverse disability in both early and late disease.
  7. Identify new strategies for patient support, symptomatic treatment and rehabilitation, in order to reduce disability and improve well-being.

Updated September 2019.